Drug Trial Radar · NCT05481151
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
Last checked: Nov 20, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
111
Actual
Start
Oct 26, 2022
Primary completion
Jun 30, 2025
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- PharmaEssentiaIndustry
- Sponsor type
- Industry
- First posted
- Aug 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV
Conditions
- Polycythemia Vera
Interventions
P1101 (Ropeginterferon alfa-2b-njft)Drug
Ropeginterferon alfa-2b-njft
Ropeginterferon alfa-2b-njft (P1101)Drug
Ropeginterferon alfa-2b-njft
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare efficacy, safety, and tolerability of P1101 utilizing 250-350-500 mcg compared to the current labeled dosing through assessing the proportion of subjects that are in a complete hematologic response at Week 24.Time frame: 24 weeks
Locations
23 sites in 2 countries. Site status is shown where the registry gives one.
Baptist MD Anderson
Jacksonville, Florida
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana
University of Kansas Medical Center
Westwood, Kansas
Mercy Health
Paducah, Kentucky
Tulane University Medical Center
New Orleans, Louisiana
American Oncology Partners of Maryland PA (Center for Cancer & Blood Disorders)
Bethesda, Maryland
Washington University School of Medicine
St Louis, Missouri
Astera HealthCare
East Brunswick, New Jersey
Mount Sinai
New York, New York
Montefiore Medical Center
The Bronx, New York
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
East Carolina University
Greenville, North Carolina
Wake Forest Baptist Medical Center
High Point, North Carolina
University of Tennessee Health Science Center
Memphis, Tennessee
MD Anderson
Houston, Texas
University of Utah
Salt Lake City, Utah
University of Virginia - Emily Couric Cancer Center
Charlottesville, Virginia
Tom Baker Cancer Centre
Calgary, Alberta, Canada
St. Paul's Hospital
Vancouver, British Columbia, Canada
Juravinski Cancer Center - Hamilton Health Sciences
Hamilton, Ontario, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.